ConductScience.org, home

Paper41999452

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.

Cetin B and 3 others. Curr Treat Options Oncol, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer. Papers, record 41999452. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41999452

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.
PubMed
Journal
Curr Treat Options Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-09-26
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cetin BBulent
2Erdem DDilek
3Karaman IIrem
4Gumusay OOzge

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Cyclin-Dependent Kinase 4Major topic
Cyclin-Dependent Kinase 6Major topic
Protein Kinase InhibitorsMajor topic
Humans
Female
Neoplasm Metastasis
Receptors, Estrogen
Receptors, Progesterone
Molecular Targeted Therapy
Drug Resistance, Neoplasm
Biomarkers, Tumor
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols
Mutation

Source PubMed

Download CSV of topics

References67

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13798106Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science1987https://conductscience.org/library/papers/3798106PubMed
237019913An emerging generation of endocrine therapies in breast cancer: a clinical perspective.NPJ Breast Cancer2023https://conductscience.org/library/papers/37019913PubMed
330069049Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.Nature2018https://conductscience.org/library/papers/30069049PubMed
430462943Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer.N Engl J Med2018https://conductscience.org/library/papers/30462943PubMed
522010023Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.J Clin Oncol2011https://conductscience.org/library/papers/22010023PubMed
639072356VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.Future Oncol2024https://conductscience.org/library/papers/39072356PubMed
731125586Targeting Nuclear Receptors with PROTAC degraders.Mol Cell Endocrinol2019https://conductscience.org/library/papers/31125586PubMed
839476340Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.N Engl J Med2024https://conductscience.org/library/papers/39476340PubMed
939265124
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
J Clin Oncol2025https://conductscience.org/library/papers/39265124PubMed
1026122181ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.Nat Rev Clin Oncol2015https://conductscience.org/library/papers/26122181PubMed
1140068598CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety.Cancer Cell2025https://conductscience.org/library/papers/40068598PubMed
1239660834Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.N Engl J Med2025https://conductscience.org/library/papers/39660834PubMed
1338824244Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.Nat Med2024https://conductscience.org/library/papers/38824244PubMed
1434392831ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Breast Cancer Res2021https://conductscience.org/library/papers/34392831PubMed
1531091374Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.N Engl J Med2019https://conductscience.org/library/papers/31091374PubMed
1630537512Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.Cancer Cell2018https://conductscience.org/library/papers/30537512PubMed
1738047585INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors.Cancer Discov2024https://conductscience.org/library/papers/38047585PubMed
1835395071Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines.Cancer Res2022https://conductscience.org/library/papers/35395071PubMed
1933705209Next-Generation Endocrine Therapies for Breast Cancer.J Clin Oncol2021https://conductscience.org/library/papers/33705209PubMed
2027717303Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.N Engl J Med2016https://conductscience.org/library/papers/27717303PubMed

See all 67 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42883867Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities.Int J Mol Sci2026https://conductscience.org/library/papers/42883867PubMed
42658220Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology.Virchows Arch2026https://conductscience.org/library/papers/42658220PubMed
42495706NUPR1 in breast cancer: mechanisms and potential applications.Front Physiol2026https://conductscience.org/library/papers/42495706PubMed
42352933CLC-Pred Synergy: Web Application for Predicting Pairwise Drug Combinations with Synergistic Activity Against NCI60 Cancer Cell Lines.Int J Mol Sci2026https://conductscience.org/library/papers/42352933PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
NR4A13164PubTator's text mininghttps://conductscience.org/library/genes/3164

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41999452

GET https://conductscience.org/api/papers/v1/41999452/references?page=2